Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CTX-110 by CRISPR Therapeutics for Follicular Lymphoma: Likelihood of Approval
CTX-110 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
CTX-110 by CRISPR Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
CTX-110 is under clinical development by CRISPR Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
CTX-110 by CRISPR Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
CTX-110 is under clinical development by CRISPR Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-110?
CTX-110 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic...